Supplementary Tables and Figures from Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes

crossref(2023)

引用 0|浏览12
暂无评分
摘要

Supp Tables and Figs

更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要